
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company in the Healthcare sector with a market capitalisation of $9.2B. Its FinScore is 48/100; its highest-scoring layer is Value (56) and its lowest is Growth (36). The shares trade at 18.1x trailing earnings and are down 16% year to date.
Share price performance
About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
www.fosunpharma.comShanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- China
- Fiscal year-end
- December
- Trading currency
- CNY
- Reporting currency
- CNY
- Fundamentals updated
- 54 days ago
- Market cap
- $9.2B
- Shares outstanding
- 2.7B
- P/E (TTM)
- 18.1x
- Dividend yield (TTM)
- 1.70%
- Beta (issuer)
- 0.43
- Revenue (latest FY)
- CN¥41.5B
Revenue breakdown
Revenue split not available
FinScore
As of 2026-10-20Snapshot
Ownership
Holder data is not available for this company yet.
Sign up or log in to see Analysis
Analysis for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is available to Finryse members. The Overview stays open to everyone; creating an account is free.